Arkolith/Insider Trading/RXDX/Form 4

McKenna Mark C.

Chairman, President & CEO, DirectorPrometheus Biosciences, Inc. (RXDX) · full profile →Form 4 · filed Mar 3, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.4M
Net Open-Market Flow
-$1.4M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2023Sell(S)11K$125.13$1.3M55K
Mar 3, 2023Option exercise(M)11K$3.70$39K66K
Mar 1, 2023Sell(S)700$125.26$88K55K
Mar 1, 2023Option exercise(M)700$3.70$3K56K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 3, 2023Option exercise(M)11K—$0482K
Mar 1, 2023Option exercise(M)700—$0492K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-016105) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML